Eli Lilly Announces $2.88 Billion Acquisition Of Merida Biosciences
Tap title to read story
Eli Lilly and Company announced a definitive agreement to acquire privately held biotechnology firm Merida Biosciences for up to $2.875 billion in cash. The transaction includes an upfront payment and contingent milestone payments, bolstering Lilly's immunology portfolio with a precision autoantibody-degradation platform. Merida’s lead experimental candidate, MER511, is currently in early-stage clinical development for autoimmune disorders including Graves' disease and thyroid eye disease. Unlike conventional therapies that broadly suppress the human immune system, Merida's protein-engineering platform selectively targets and eliminates disease-causing autoantibodies while maintaining normal immune function. Propelled by surging commercial demand and robust revenues from its metabolic and diabetes treatments, Eli Lilly has maintained an active acquisition strategy throughout the year. Industry analysts note that the transaction is subject to customary closing conditions and regulatory clearances, with corporate leadership anticipating final completion during the fourth quarter of 2026.
Timeline
- On April 10, 2025 Merida Biosciences secured series funding for technology development.
- On December 10, 2025 Merida Biosciences initiated phase 1 clinical trials for MER511.
- On August 25, 2026 executives finalized preliminary corporate buyout terms and conditions.
- On August 30, 2026 board directors approved the multi-billion-dollar acquisition agreement.
- On August 31, 2026 Eli Lilly announced the definitive acquisition agreement publicly.
- On August 31, 2026 financial markets analyzed pharmaceutical sector consolidation and valuations.
- In September 2026 regulatory bodies will review antitrust and merger compliance documents.
- In October 2026 shareholders will vote on transaction approval protocols.
- In November 2026 clinical trial programs will transition under new corporate ownership.
- In fourth quarter 2026 the corporate acquisition is scheduled to close.
Sources
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.






























